Drugs / SYS6045
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07122063 | Aug 2025 → Jul 2027 expected | cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-01-07 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYS6045 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the ‘‘Board ’’) of CSPC Pharmaceutical Group Limited (the ‘‘Company ’’, together with its subsidiaries, the ‘‘Group ’’) is pleased to announce that SYS6045 (antibody-drug conjugate) (the ‘‘Product ’’) developed by the Group has obtained clinical trial approva l granted by the National Medical Products Administration of the People ’s Republic of China to conduct clinical trials in China. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-01-07 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYS6045 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07122063 ↗ |